CSL Limited

CSL Limited is an Australian multinational biotechnology company whose principal activities are the research, development, manufacture, and marketing of specialized medicines and vaccines. Its business is organized around products derived from human blood plasma, influenza and other vaccines, specialty pharmaceuticals, and therapies for immune, bleeding, respiratory, renal, and other serious conditions. The company also produces antivenoms and selected products used in biomedical research and biomanufacturing. The organization began in 1916 as Commonwealth Serum Laboratories, an Australian government laboratory established to improve the domestic supply of vaccines and other biological products. It started operations in Melbourne in 1918 and moved to purpose-built facilities at Parkville in 1919. During its early decades, CSL manufactured insulin, vaccines, antivenoms, immunoglobulins, and other products that had previously been difficult to obtain in Australia. Its history includes important public-health work, but also the 1928 Bundaberg tragedy, in which a diphtheria toxin-antitoxin product manufactured by CSL was associated with the deaths of twelve children. Investigations did not attribute the deaths to the laboratory's manufacturing process, but identified labeling failures, contributing to a lasting emphasis on quality control and product safety. CSL expanded its scientific and manufacturing capabilities through work on antivenoms, penicillin, plasma fractionation, blood products, and vaccines. Plasma fractionation began in 1952, creating the foundation for the modern plasma-products business. Later achievements included tetanus and combination vaccines, polio-vaccine production, Rhesus immunoglobulin, and heat-treatment methods intended to reduce the risk of infectious transmission from blood and plasma products. CSL also contributed to the development of Gardasil through collaboration involving Australian researcher Ian Frazer and other partners. The company was privatized by the Australian government in 1994 and listed on the Australian Securities Exchange. Its international scale increased substantially through the acquisition of ZLB Bioplasma in 2000 and Aventis Behring in 2004. These transactions created the basis for CSL Behring, the group's major plasma-derived and specialty-biologics business. CSL subsequently expanded its vaccines business by acquiring Novartis's global influenza-vaccine business in 2015 and combining it with BioCSL under the Seqirus name. The group later acquired Calimmune's stem-cell-therapy platform and Vitaeris, and agreed to acquire Vifor Pharma, strengthening its specialty-pharmaceutical and renal-care portfolio. CSL's principal operating businesses are CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor. CSL Behring develops plasma-derived and recombinant therapies for immune deficiencies, bleeding disorders, hereditary angioedema, respiratory disease, and critical-care applications. CSL Plasma operates a large international network of plasma-collection centers that supplies fractionation operations. CSL Seqirus is a major influenza-vaccine producer and also supplies selected travel, pandemic, and specialty vaccines, as well as Australian antivenoms. CSL Vifor focuses on medicines for iron deficiency, kidney disease, dialysis-related care, and related specialty conditions. The company retained a prominent role in Australia's response to the COVID-19 pandemic. In 2020, it entered agreements concerning manufacture of the Oxford-AstraZeneca vaccine and supply of the University of Queensland vaccine candidate. The Queensland candidate was discontinued after trial participants produced false-positive HIV test results. CSL subsequently manufactured Oxford-AstraZeneca doses at its Broadmeadows facility for the Australian government. Today, CSL remains headquartered in Melbourne and operates research, manufacturing, plasma-collection, and commercial facilities across Australia, the Unite…

CSL was established in 1916 as Commonwealth Serum Laboratories, a body of the Australian government created to develop and manufacture vaccines and other biological products for domestic use. It began operating in Melbourne in 1918 in premises associated with the Walter and Eliza Hall Institute and moved to a purpose-built Parkville site the following year. Under its first director, William Penfold, the laboratory developed production capabilities for vaccines, insulin, antitoxins, and other medical products. The institution faced a major crisis in 1928 when a diphtheria toxin-antitoxin batch was connected with the deaths of twelve children in Bundaberg, Queensland. Reviews concluded that the manufacturing process itself had not caused the contamination, but found that labeling procedures were inadequate. The event became a defining lesson in biological-product regulation and safety. During the same period, CSL began systematic antivenom work with researchers associated with the Walter and Eliza Hall Institute. Antivenom for tiger-snake bites was clinically tested in 1930 and commercially released in 1931. Research later expanded to antivenoms for additional snakes, spiders, marine animals, and other Australian hazards. CSL developed further biological-manufacturing capacity during the 1930s and 1940s. Its scientists worked on influenza and polio research with external collaborators, and the organization began producing penicillin in 1944, an important wartime contribution. It also produced insulin for Australian patients, introduced tetanus vaccination, and developed combination vaccines against diphtheria, tetanus, and whooping cough. In 1952, CSL began plasma fractionation. This enabled the production of albumin, immunoglobulins, clotting factors, and related blood-derived therapies and gradually shifted the institution toward the specialty-biotechnology model it retains today. During the 1950s and 1960s, CSL expanded its vaccine, antivenom, and blood-products portfolio. It adopted polio-vaccine production, created polyvalent antivenoms, and developed Rhesus immunoglobulin to reduce the risk of hemolytic disease in newborns. Later, the company pioneered heat-treatment approaches for blood and plasma products designed to reduce infectious risks, including HIV transmission. CSL also participated in the broader scientific and commercial development of human papillomavirus vaccination, which ultimately contributed to Gardasil. The Australian government privatized CSL in 1994. The company was converted into CSL Limited and listed on the Australian Securities Exchange through an initial public offering. International expansion accelerated in 2000 when CSL acquired Swiss plasma company ZLB Bioplasma AG. In 2004 it purchased Aventis Behring, a German-based medical-products business. The combined operations became the foundation of CSL Behring and gave CSL a much larger global plasma-collection, fractionation, and specialty-therapeutics platform. CSL continued to broaden its vaccine activities. In 2014, Novartis announced the sale of its influenza-vaccine business to CSL, and the transaction was completed in 2015. The acquired business was combined with BioCSL and rebranded Seqirus, creating one of the world's largest influenza-vaccine companies. CSL later acquired Calimmune's stem-cell-therapy platform and announced the acquisition of Vitaeris. In 2021, it agreed to acquire Vifor Pharma, adding a substantial specialty-pharmaceutical business focused particularly on iron deficiency and kidney disease. The transaction led to the formation of CSL Vifor within the group's operating structure. During the COVID-19 pandemic, CSL entered agreements with the Australian government relating to both the University of Queensland vaccine candidate and manufacture of the Oxford-AstraZeneca vaccine. The Queensland candidate was abandoned after vaccine-induced antibodies caused false-positive HIV test results in trial participants. CSL nevertheless proceeded with domestic production of Oxford-AstraZeneca vaccine, with the first batches receiving provisional approval in March 2021. In 2022, the company aligned its divisional identities under the CSL master brand. Its current businesses encompass plasma collection, plasma-derived and recombinant therapies, vaccines, antivenoms, and specialty pharmaceuticals, supported by facilities and commercial operations across Australia, the United States, Europe, and other markets.

1. 2022Operating divisions unified under CSL master brand

   The group's divisions are renamed CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.

   Source
2. 2021Australian production of Oxford-AstraZeneca vaccine approved

   Australia's regulator provisionally approves initial Oxford-AstraZeneca COVID-19 vaccine batches manufactured by CSL.

   Source
3. 2015Seqirus created

   CSL combines its BioCSL vaccine activities with Novartis's acquired influenza-vaccine business and launches the Seqirus brand.

   Source
4. 2004Aventis Behring acquired

   CSL acquires Aventis Behring, expanding its plasma-derived and specialty-biologics operations.

   Source
5. 2000ZLB Bioplasma acquired

   CSL acquires Swiss plasma company ZLB Bioplasma AG, materially increasing its international scale.

   Source
6. 1994Privatization and ASX listing

   The Australian government privatizes CSL, which becomes CSL Limited and is listed on the Australian Securities Exchange.

   Source
7. 1952Plasma fractionation begins

   The company commences plasma fractionation, establishing the technical basis for its modern plasma-derived medicines business.

   Source
8. 1944Penicillin production begins

   CSL begins producing penicillin during the Second World War.

   Source
9. 1931Commercial tiger-snake antivenom released

   Following clinical testing, CSL commercially releases antivenom for tiger-snake envenomation.

   Source
10. 1918Operations begin in Melbourne

    CSL begins operating in Melbourne in premises associated with the Walter and Eliza Hall Institute.

    Source
11. 1916Commonwealth Serum Laboratories established

    The Australian government establishes Commonwealth Serum Laboratories to develop and manufacture vaccines and other biological products.

    Source

Specialty biotechnology and biopharmaceutical group focused on plasma-derived therapies, vaccines, and medicines for serious and rare diseases.

• CSL Behring plasma-derived therapiesPlasma-derived medicines

  CSL Behring supplies immunoglobulins, albumin, coagulation factors, fibrinogen, antithrombin, C1-esterase inhibitor, and other plasma-derived products. These therapies are used in primary and secondary immune deficiencies, hemophilia and other bleeding disorders, hereditary angioedema, critical care, and replacement of specific plasma proteins. Representative brands include Privigen, Hizentra, Berinert, Humate-P, Rhophylac, and Albumin products. Availability and formulation vary by country.

• CSL Seqirus influenza vaccinesVaccines

  CSL Seqirus develops and manufactures seasonal influenza vaccines for different age groups and markets. Its portfolio has included Afluria and Afluria Quadrivalent, Fluad and Fluad Quadrivalent, and cell-based or adjuvanted influenza products marketed under different names according to national registration. Seqirus also maintains pandemic-influenza capabilities and supplies vaccines internationally.

• Australian antivenomsAntivenoms1931

  CSL's antivenom portfolio covers medically important Australian snakes, spiders, and marine animals. Products have included tiger-snake, taipan, brown-snake, death-adder, funnel-web-spider, redback-spider, stonefish, sea-snake, and box-jellyfish antivenoms, together with polyvalent snake antivenom and the Snake Venom Detection Kit. These products originated in the laboratory's long-standing Australian venom-research program.

• Q-VAXVaccine

  Q-VAX is a vaccine against Q fever caused by Coxiella burnetii. It has been used in Australia for people whose occupations or activities create elevated exposure risk, subject to applicable medical screening and regulatory requirements.

• CSL Vifor specialty medicinesSpecialty pharmaceuticals2022

  CSL Vifor extends the group into specialty pharmaceuticals, particularly treatments for iron deficiency, anemia associated with kidney disease, and conditions managed in nephrology and dialysis settings. The business joined CSL following the acquisition of Vifor Pharma and complements the group's existing biologics and hospital-care activities.

• 2021Acquire Vifor PharmaM&A

  CSL sought to diversify beyond plasma products and vaccines into specialty pharmaceuticals, particularly renal and iron-deficiency care.

  What changed. CSL announced an agreement to acquire Swiss pharmaceutical company Vifor Pharma.

  Aftermath. Vifor became CSL Vifor and added specialty medicines and a substantial nephrology-focused commercial platform.

  Announced transaction value. US$11.7 billion (December 2021 announcement)

  Source
• 2020Support COVID-19 vaccine development and manufactureProduct launch

  Australia sought domestic access to COVID-19 vaccines and local manufacturing capacity during the pandemic.

  What changed. CSL signed agreements concerning the University of Queensland vaccine candidate and manufacture of the Oxford-AstraZeneca vaccine.

  Aftermath. The University of Queensland candidate was discontinued after false-positive HIV test results, while CSL proceeded with Australian production of Oxford-AstraZeneca vaccine.

  Source
• 2015Combine BioCSL with Novartis influenza vaccinesM&A

  CSL wanted to build a larger global influenza-vaccine platform.

  What changed. CSL acquired Novartis's influenza-vaccine business and combined it with BioCSL under the Seqirus name.

  Aftermath. Seqirus became a major international influenza-vaccine business within CSL.

  Acquisition consideration. A$275 million (2014 announcement)

  Source
• 2004Acquire Aventis BehringM&A

  CSL aimed to extend its plasma-products and specialty-medical operations beyond Australia.

  What changed. The company acquired Aventis Behring and integrated the business into the CSL group.

  Aftermath. The enlarged business became the foundation of CSL Behring and strengthened CSL's position in therapies for immune and bleeding disorders.

  Source
• 2000Acquire ZLB BioplasmaM&A

  CSL sought greater international scale in plasma collection, fractionation, and plasma-derived medicines.

  What changed. CSL acquired Swiss plasma company ZLB Bioplasma AG.

  Aftermath. The acquisition substantially expanded CSL's plasma business and international operating base.

  Source
• 1994Proceed with privatization and public listingStrategy

  CSL had operated as an Australian government laboratory since its creation.

  What changed. The government privatized the organization as CSL Limited and listed it on the Australian Securities Exchange.

  Aftermath. The listing provided a platform for international acquisitions and the transformation of CSL into a global biotechnology group.

  Source

• 2010Investigation of febrile convulsions after H1N1 vaccinationControversy

  Australian authorities investigated febrile convulsions reported in children after administration of CSL's Panvax and Panvax Junior pandemic H1N1 vaccines. Scientific publications proposed that a manufacturing-process factor might have contributed, although the event is best described as a regulatory and vaccine-safety investigation rather than a finding of intentional misconduct.

  Source
• 1928Bundaberg diphtheria tragedyControversy

  A diphtheria toxin-antitoxin batch associated with CSL was linked to the deaths of twelve children in Bundaberg, Queensland. Investigations did not find that the manufacturing process caused the deaths, but identified labeling failures. The incident became a major historical lesson in biological-product safety and quality control.

  Source

• 2022CSL adopts unified divisional naming structure

  CSL rebranded its operating divisions under the CSL name, creating CSL Behring, CSL Plasma, CSL Seqirus, and CSL Vifor.

  Other
  Source
• 2021CSL manufactures first Australian batches of Oxford-AstraZeneca vaccine

  Australia's Therapeutic Goods Administration provisionally approved the first batches of Oxford-AstraZeneca COVID-19 vaccine manufactured by CSL at Broadmeadows, Victoria.

  Product launchRegulation
  Source
• 2021CSL agrees to acquire Vifor Pharma

  CSL announced an agreement to acquire Swiss specialty-pharmaceutical company Vifor Pharma, expanding its presence in renal care, iron deficiency, and specialty medicines.

  M&A
  Source
• 2020CSL and Australian government sign COVID-19 vaccine agreements

  CSL agreed to supply the University of Queensland vaccine candidate and manufacture the Oxford-AstraZeneca vaccine for Australia, subject to clinical and regulatory outcomes.

  Product launchOther
  Source
• 2020University of Queensland vaccine program discontinued

  The University of Queensland vaccine candidate supported by CSL was discontinued after trial participants returned false-positive HIV test results caused by vaccine-induced antibodies.

  OtherRegulation
  Source

1. CSL Limited